We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Galena Biopharma

News List

Galena Biopharma merges SELLAS to form new combined company pharmaceutical-technology
August 11, 2017
SELLAS is a privately held, oncology-focused, clinical stage biopharmaceutical company. The newly formed company will feature a late-stage pipeline focusing on the development of new immunotherapies targeting a wide range of indications in haematology an
Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants firstwordpharma
February 14, 2017
Galena Biopharma, Inc. announced the closing of its previously announced underwritten public offering of 17,000,000 shares of common stock and warrants to purchase 17,000,000 shares of common stock priced at $1.00 per share and accompanying warrant.
Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants firstwordpharma
February 09, 2017
Galena Biopharma, Inc. today announced the pricing of an underwritten public offering of units with anticipated gross proceeds of $17,000,000, before deducting underwriting discounts and commissions and estimated offering expenses payable by Galena.